Bing

MannKind (NASDAQ:MNKD) was downgraded by stock analysts at Vetr from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday, MarketBeat.com reports. They presently …
Ticker Report · 8/28/2015
Some of the biggest gainers among healthcare stocks include: Mannkind Corp (MNKD): MNKD stock is up 7.9% today. Neurocrine Biosciences (NBIX): NBIX stock is up 7.1% today. Amag Pharmaceuticals (AMAG): AMAG stock is up 7.1% today. Acadia …
Investor Place · 8/26/2015
If the shares can continue to outperform, there's plenty of sideline cash to drive them higher. Next is MNKD. The biotech stock sports only two negative Septembers going back to 2005 -- albeit they're the two most …
Schaeffer's Investment Research · 8/26/2015
More from Bing News
and expand market reach ought to also allay investors' concerns about the marketing partner's commitment to Afrezza. All in all, we don't think the favorable long-term outlook for MNKD stock has changed, the recent price action notwithstanding.
Seeking Alpha · 8/17/2015
convertible debt
CHICAGO, Aug. 27, 2015 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOOG, W, MNKD, AVGO and NKE. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by …
Market Watch · 8/28/2015
Google Inc
Vetr upgraded shares of MannKind (NASDAQ:MNKD) from a buy rating to a strong-buy rating in a report released on Monday, AnalystRatings.Net reports. Vetr currently has $4.44 price objective on the biopharmaceutical company’s stock. Shares of …
wkrb13.com · 8/25/2015
CHICAGO, Aug. 17, 2015 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PYPL, MNKD, SYY, RIG and SRPT. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by …
Financial Content · 8/17/2015
Sarepta Therapeutics
A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech ... MannKind Corp. (NASDAQ: MNKD) saw its short interest increase to 121.78 million shares. The previous reading …
24/7 Wall ST · 8/26/2015
In a report published on Tuesday, Goldman Sachs downgraded MannKind Corporation (NASDAQ:MNKD) stock from a Neutral to a Sell rating, and cut the price target from $6 to $3. As the news crossed the wires, the stock is trading down 13.14% at $5.78 …
bidnessetc.com · 3/4/2015
NEW YORK (TheStreet) -- MannKind (MNKD) shares are gaining 0.25% to $4.04 in after-hours trading on Monday after the company reported its fiscal 2015 second quarter earnings results before the opening bell today that beat analysts' estimates. For the ...
The Street · 8/10/2015